口咽与喉癌选择性颈部放疗剂量与体积降级的前瞻性2期研究
这项前瞻性双中心2期研究纳入72例口咽或喉鳞癌患者,探索减少选择性颈部照射体积与剂量(40 Gy/20次)的疗效与耐受性。中位随访24.7个月,无孤立选择性淋巴结复发,7例淋巴结复发中5例野内、2例选择性区域同步野内复发。1年患者报告结局除唾液和味觉外优于或等同于基线。
要点
- 口咽癌仅照射受累及紧邻淋巴结站,喉癌至少双侧II、III区,III区受累才照射IV区。
- 选择性剂量40 Gy/20次,受累淋巴结推量30 Gy/15次,可疑淋巴结推量24 Gy/15次。
- 中位随访24.7个月无孤立选择性淋巴结复发,支持选择性剂量体积降级肿瘤学安全。
核心结论
- 对于口咽和喉癌调强放疗,选择性颈部剂量与体积降级在肿瘤学上是合理的,患者报告结局有前景。
研究设计与样本
- 分期为I-II期5例、III期17例、IV期50例,90%接受放化疗。
主要发现
- 中位随访24.7个月,无孤立选择性淋巴结复发。
- 7例出现淋巴结复发,其中5例野内复发、2例选择性区域复发伴同步野内复发。
- 1年患者报告结局除唾液和味觉外优于或等同于基线。
关键数值与推荐
- 口咽癌仅照射受累及紧邻淋巴结站至40 Gy/20次。
- 喉癌至少照射双侧II和III区至40 Gy,III区受累时才照射IV区。
- 受累淋巴结推量30 Gy/15次,可疑淋巴结推量24 Gy/15次。
- T3N0-1和IVA/B期患者需同步化疗。
临床怎么用
- 口咽和喉癌调强放疗可考虑减少选择性颈部照射体积与剂量至40 Gy/20次。
- 根据影像学将淋巴结分为受累或可疑,分别给予不同推量剂量。
- 喉癌选择性照射至少包括双侧II和III区,III区受累时加照IV区。
局限性
- 样本量较小(72例),随访时间较短(中位24.7个月)。
- 为单臂2期研究,无随机对照。
- 唾液和味觉患者报告结局未优于基线。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The required elective nodal dose and volumes for head and neck intensity modulated radiation therapy have largely been extrapolated from conventional radiation therapy fields. In this prospective, dual-center, phase 2 study, we investigated the efficacy and tolerability of reduced elective nodal volume and dose in oropharyngeal and laryngeal squamous cell carcinoma. METHODS AND MATERIALS: Patients with newly diagnosed squamous cell carcinoma of the oropharynx and larynx were eligible for enrollment. Each lymph node was characterized as involved or suspicious based on imaging criteria. For oropharynx cancer, only involved and immediately adjacent stations were treated to 40 Gy in 20 fractions. In larynx patients, at least bilateral levels II and III were treated to 40 Gy, with level IV treated only if level III was involved. Involved and suspicious nodes were then boosted with 30 Gy and 24 Gy in 15 fractions, respectively. Concurrent chemotherapy was required for stage T3N0-1 and IVA/B patients. The primary endpoint of the study was solitary elective volume recurrence, with secondary endpoints including patterns of failure and patient-reported outcomes. RESULTS: A total of 72 (51 oropharynx, 21 larynx) patients completed treatment on this trial from January 2017 through November 2018. The stages at presentations were 5, 17, and 50 stage I-II, III, and IV, respectively, with 90% treated with chemoradiation therapy. At a median follow-up of 24.7 months for surviving patients, there have been no solitary elective nodal recurrences. Seven patients developed a nodal recurrence, 5 of which were in-field and 2 were elective with synchronous in-field recurrence. Patient-reported outcomes assessment at 1 year showed superior or equivalent outcomes compared with baseline, except for saliva and taste measures. CONCLUSIONS: The results of this trial suggest that elective dose and volume reduction is oncologically sound for oropharyngeal and laryngeal cancer treated with intensity modulated radiation therapy, with promising quality-of-life outcomes.
引用
- Sher DJ, Pham NL, Shah JL, et al. Prospective Phase 2 Study of Radiation Therapy Dose and Volume De-escalation for Elective Neck Treatment of Oropharyngeal and Laryngeal Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 33127491. doi:10.1016/j.ijrobp.2020.09.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。